利用丰富的乙炔通过1,2-双官能化直接粘合两个分子来生产内烯烃的方法非常有限。由于乙炔和所产生的烯烃之间潜在的竞争反应以及处理这种有害试剂和控制区域的困难,以期望的方式通过 1,2-双官能化将气态乙炔转化为内部烯烃并不像预期的那么容易。和立体选择性。在这项工作中,我们设计了一种高效的催化系统,用于将乙炔气体合并到巨大的( E )-β-溴乙烯基砜中,该系统稳定、易于操作,并且可以作为双功能乙炔,并在催化反应中表现出丰富的反应活性。 Sonogashira偶联、Heck偶联、取代反应以及各种脱磺酰化转化,提供了大量的内烯烃。
Organic-photoredox-catalyzed three-component sulfonylative pyridylation of styrenes
作者:Fang Wang、Jian Qin、Shengqing Zhu、Lingling Chu
DOI:10.1039/d0ra10180j
日期:——
An efficient, metal-free protocol for the three-component sulfonylative pyridylation of alkenes via organic-photoredox catalysis is described.
一种高效、无金属的三组分烯烃磺酰基化吡啶化方法,通过有机光还原催化实现。
CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY
申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
公开号:EP1173472A1
公开(公告)日:2002-01-23
US6884868B1
申请人:——
公开号:US6884868B1
公开(公告)日:2005-04-26
[EN] CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY<br/>[FR] HEXAPEPTIDES CYCLIQUES À ACTION ANTIBIOTIQUE
申请人:FUJISAWA PHARMACEUTICAL CO
公开号:WO2000064927A1
公开(公告)日:2000-11-02
This invention relates to new polypeptide compound represented by general formula (I), wherein R?1, R2, R3, R4, R5 and R6¿ are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical compositon comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
Cyclic hexapeptides having antibiotic activity
申请人:Tojo Takashi
公开号:US06884868B1
公开(公告)日:2005-04-26
This invention relates to new polypeptide compound represented by general formula (I), wherein R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including
Pneumocystis carinii
infection (e.g.
Pneumocystis carinii
pneumonia) in a human being or an animal.